

## Vimpat<sup>®</sup> (lacosamide) – First-time generic

- On April 8, 2022, <u>Indoco Remedies</u> and <u>Sagent Pharmaceuticals launched</u> <u>AP-rated</u> generic versions of UCB's <u>Vimpat (lacosamide)</u> injection.
- Vimpat is approved for the treatment of partial-onset seizures in patients 1 month of age and older, and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Vimpat is also available as a brand oral solution and generic <u>tablet</u> that carry similar indications as the injection.
- According to IQVIA, Vimpat injection had annual sales of \$43.8 million.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.